Kinase Mutations as Predictive Biomarkers in Hematolymphoid Malignancies

Targeted therapeutics against kinases has been employed in the clinic for over a decade. Their use of ten times requires concomitant molecular diagnostics evaluating the mutational status of the targeted kinases. While kinase mutations function as diagnostic and prognostic biomarkers in hematolymphoid malignancies, in this review, we focus on kinase mutations with predictive utility and their relevance to molecular diagnostics.